These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 29270749

  • 21. [BIOMARKERS OF EARLY AND DIFFERENTIAL DIAGNOSIS OF PROSTATIC CANCER].
    Grygorenko VM, Danylets RO, Vikarchuk MV, Gorbahn LV, Klepko AV.
    Klin Khir; 2017; (1):54-7. PubMed ID: 30272918
    [Abstract] [Full Text] [Related]

  • 22. Comparison of serum acetyl hydrolase (PAF-AH) and paraoxonase 1 (PON1) values between prostate cancer patients and a control group.
    Benli E, Bayrak A, Cirakoglu A, Bayrak T, Noyan T.
    Kaohsiung J Med Sci; 2017 Nov; 33(11):572-577. PubMed ID: 29050675
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of the plasma level of long non-coding RNA PCAT1 in prostatic hyperplasia and newly diagnosed prostate cancer patients.
    Rezatabar S, Moudi E, Sadeghi F, Khafri S, Kopi TA, Parsian H.
    J Gene Med; 2020 Oct; 22(10):e3239. PubMed ID: 32529802
    [Abstract] [Full Text] [Related]

  • 24. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
    Coelho FF, Guimarães FL, Cabral WL, Salles PG, Mateo EC, Nogueira e Nogueira LM, Fonseca CE, Gomes KB.
    Genet Mol Res; 2015 Oct 28; 14(4):13519-31. PubMed ID: 26535666
    [Abstract] [Full Text] [Related]

  • 25. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.
    Eur Urol; 2006 Feb 28; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [Abstract] [Full Text] [Related]

  • 26. Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer.
    Mengus C, Le Magnen C, Trella E, Yousef K, Bubendorf L, Provenzano M, Bachmann A, Heberer M, Spagnoli GC, Wyler S.
    J Transl Med; 2011 Sep 26; 9():162. PubMed ID: 21943235
    [Abstract] [Full Text] [Related]

  • 27. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM, Thuler LC, Matos AR, Coutinho-Camillo CM, Soares FA, da Silva EA, Neves AF, Goulart LR, Gimba ER.
    Exp Mol Pathol; 2012 Feb 26; 92(1):13-9. PubMed ID: 21963599
    [Abstract] [Full Text] [Related]

  • 28. [Biomarkers of prostate cancer and potential for using ace produced in prostate gland for diagnosis of prostate cancer and benign prostatic hyperplasia].
    Kamalov AA, Samokhodskaya LM, Karpov VK, Okhobotov DA, Mamedov VN.
    Urologiia; 2019 Jun 26; (2):73-81. PubMed ID: 31162906
    [Abstract] [Full Text] [Related]

  • 29. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
    Stephan C, Lein M, Jung K, Schnorr D, Loening SA.
    Cancer; 1997 Jan 01; 79(1):104-9. PubMed ID: 8988733
    [Abstract] [Full Text] [Related]

  • 30. Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics.
    Kim EA, Kim YH, Kang HW, Yoon HY, Kim WT, Kim YJ, Yun SJ, Moon SK, Choi YH, Kim IY, Lee SC, Kim WJ.
    J Korean Med Sci; 2015 Jul 01; 30(7):937-42. PubMed ID: 26130958
    [Abstract] [Full Text] [Related]

  • 31. Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: an independent cancer biomarker.
    Korbakis D, Gregorakis AK, Scorilas A.
    Clin Chem; 2009 May 01; 55(5):904-13. PubMed ID: 19299547
    [Abstract] [Full Text] [Related]

  • 32. Prostate cancer antigen 3 gene expression in peripheral blood and urine sediments from prostate cancer and benign prostatic hyperplasia patients versus healthy individuals.
    Moradi Sardareh H, Goodarzi MT, Yadegar-Azari R, Poorolajal J, Mousavi-Bahar SH, Saidijam M.
    Urol J; 2014 Nov 30; 11(6):1952-8. PubMed ID: 25433473
    [Abstract] [Full Text] [Related]

  • 33. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
    Kang HW, Lee HY, Byun YJ, Jeong P, Yoon JS, Kim DH, Kim WT, Kim YJ, Lee SC, Yun SJ, Kim WJ.
    Investig Clin Urol; 2020 Jul 30; 61(4):411-418. PubMed ID: 32665998
    [Abstract] [Full Text] [Related]

  • 34. Identification of Differential Patterns of Oxidative Biomarkers in Prostate Cancer Progression.
    Wu T, Kasper S, Wong RM, Bracken B.
    Clin Genitourin Cancer; 2020 Apr 30; 18(2):e174-e179. PubMed ID: 31899150
    [Abstract] [Full Text] [Related]

  • 35. Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort.
    Adeola HA, Smith M, Kaestner L, Blackburn JM, Zerbini LF.
    Oncotarget; 2016 Mar 22; 7(12):13945-64. PubMed ID: 26885621
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness.
    Piao XM, Byun YJ, Jeong P, Ha YS, Yoo ES, Yun SJ, Kim WJ.
    Clin Genitourin Cancer; 2017 Aug 22; 15(4):450-454. PubMed ID: 27842896
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.